Evidence map›Paper›PMID 40908521›Full record

ReviewCurrent protein & peptide science2026

The Emergence of Bioactive Peptides as Anti-diabetic Agents: A Review.

Ramanand, Rohit Singh, Vedpal Singh, Archita Katrolia

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current protein & peptide science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

RamanandMedicinal and Process Chemistry, CSIR-Central Drug Research Institute, Lucknow, U.P, 226031, India.ORCID 0000-0003-4396-7505
Rohit SinghMedicinal and Process Chemistry, CSIR-Central Drug Research Institute, Lucknow, U.P, 226031, India.ORCID 0000-0001-8542-6534
Vedpal SinghDepartment of Pharmacognosy, College of Pharmacy, JSS University, C-20/1, Sector-62, Noida, U.P, 201301, India.ORCID 0000-0003-3523-1469
Archita KatroliaDepartment of Pharmaceutics, College of Pharmacy, JSS University, C-20/1, Sector-62, Noida, U.P, 201301, India.ORCID 0000-0002-2958-0964

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A complex condition called diabetes mellitus is characterized by insufficient or resistant insulin production. The incidence of diseases is rising quickly, placing a significant economic, social, and health burden on the modern world. Interventions in nutrition and improved physical activity could make a big difference in controlling this disease. Bioactive peptides obtained from natural sources have been linked to various therapeutic benefits. Several peptides with anti-diabetic potential may lower blood sugar levels, enhance insulin uptake, and inhibit vital enzymes involved in the onset and progression of diabetes. Many bioactive peptides with anti-diabetic properties have been discovered and validated. A more transparent comprehension of the underlying molecular mechanisms of these peptides will aid the development of new peptide-based pharmaceuticals. The objective of this review was to update our understanding of the genesis, structural features, and mechanism of action. The effects of bioactive peptides on vital enzymes and proteins, such as α- glucosidase, α-amylase, glucagon-like peptides, and dipeptidyl peptidase-IV, which are involved in managing glycaemic levels from carbohydrate consumption through blood glucose regulation, were also addressed..The information obtained through this study and industry endeavours should provide a better understanding and evaluation of the prospects of bioactive peptides with antidiabetic potential for blood glucose level management.

Indexed as

Diabetes Mellitus, Type 2Hypoglycemic AgentsPeptidesalpha-Amylasesalpha-GlucosidasesAnimalsBioactive Peptides, DietaryBlood GlucoseDipeptidyl Peptidase 4Glucagon-Like PeptidesGlycoside Hydrolase InhibitorsHumansInsulinalpha-Amylasesalpha-GlucosidasesBioactive Peptides, DietaryBlood GlucoseDipeptidyl Peptidase 4Glucagon-Like PeptidesGlycoside Hydrolase InhibitorsHypoglycemic AgentsInsulinPeptidesAnti-diabetic propertiesbioactive peptidesdipeptidyl peptidase IV inhibitorsglucagon-like peptide-1α-amylase inhibitorα-glucosidase inhibitor

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.